Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
2013
|
| gptkbp:ATCCode |
A10BK
|
| gptkbp:contraindication |
gptkb:type_1_diabetes_mellitus
severe renal impairment |
| gptkbp:discoveredBy |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:drugInteraction |
gptkb:insulin
diuretics sulfonylureas |
| gptkbp:effect |
lower blood glucose
lower blood pressure increase urinary glucose excretion promote natriuresis reduce HbA1c reduce albuminuria reduce body weight reduce risk of cardiovascular death reduce risk of cardiovascular events reduce risk of end-stage kidney disease reduce risk of hospitalization for heart failure reduce risk of major adverse cardiovascular events slow progression of kidney disease |
| gptkbp:eliminatedIn |
renal
|
| gptkbp:halfLife |
10-13 hours
|
| gptkbp:hasApprovedDrug |
gptkb:dapagliflozin
gptkb:empagliflozin gptkb:canagliflozin gptkb:ertugliflozin |
| https://www.w3.org/2000/01/rdf-schema#label |
SGLT2 inhibitors
|
| gptkbp:mechanismOfAction |
inhibit sodium-glucose co-transporter 2
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:notEffectiveAgainst |
gptkb:type_1_diabetes_mellitus
|
| gptkbp:regulates |
FDA approved
EMA approved |
| gptkbp:riskFactor |
gptkb:Fournier's_gangrene
amputation (canagliflozin) bone fracture (canagliflozin) |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
urinary tract infections
genital mycotic infections euglycemic diabetic ketoacidosis volume depletion |
| gptkbp:target |
gptkb:SGLT2_protein
|
| gptkbp:usedFor |
gptkb:type_2_diabetes_mellitus
heart failure chronic kidney disease |
| gptkbp:bfsParent |
gptkb:Type_2_diabetes
|
| gptkbp:bfsLayer |
5
|